By Alan Johnson and Luke Maunder, Bristows
There is a lot of talk about the consequences of an ineffective opt-out, but concentrating on this issue perhaps ignores a more basic one: can anyone even…
The 30-day period to initiate mandatory arbitration proceedings against apllicants of authorization to introduce generic medicines in the market is an expiration or final term.
A full summary of this…
The Court of Intellectual Property has exclusive jurisdiction to revoke patents. The mandatory arbitration court established by Law 62/2011 cannot declare the nullity of a pharmaceutical patent even…
The Patent Trial and Appeal Board did not err in instituting Covered Business Method ("CBM") review and finding several claims of a financing method patent owned by Credit Acceptance Corporation ("…
Another significant delay - or even more substantial - trouble seems to be ahead of the Unitary Patent system, due to today's decision of the German Constitutional Court (Bundesverfassungsgericht) in…
Although the title of this blog will sound trite to many friends accustomed to arguing patent cases before the European Patent Office, it does not sound so trite when read against the background of…
The previously announced target date for the entry into operation of the Unified Patent Court, envisaged for December 2017, cannot be maintained. This has been reported by the UPC Preparatory…
ECC’s patent strategy not Swiss courts' cup of tea
Ethical Coffee Company (ECC) and different entities of the Nestlé group of companies have been involved in many legal disputes in various…
Second medical use cases have been making their way through patent courts around the world. In the Novartis / Sun litigation the Hague Court of Appeal (PI decision) and District Court (interlocutory…
On March 22, 2017, the Beijing IP Court (the “trial court”) issued a decision on a high-profile case Iwncomm v. Sony concerning infringement of a standard essential patent (SEP). This case has drawn…
